Treatment of ADA2 deficiency involves anti-tumor necrosis factor alpha agents, which prevent and eliminate manifestations of autoinflammatory disease, reduce the risk of ischemic stroke, and relieve immunodeficiency.5 The gene discussed is ADA2; the disease is hyperinsulinemic hypoglycemia, familial, 4.